1
|
Sun F, Zhao W, Shen H, Fan N, Zhang J, Liu Q, Xu C, Luo J, Zhao M, Chen Y, Lam KWK, Yang X, Kwok RTK, Lam JWY, Sun J, Zhang H, Tang BZ. Design of Smart Aggregates: Toward Rapid Clinical Diagnosis of Hyperlipidemia in Human Blood. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2022; 34:e2207671. [PMID: 36134528 DOI: 10.1002/adma.202207671] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 09/10/2022] [Indexed: 06/16/2023]
Abstract
Molecular aggregates with environmental responsive properties are desired for their wide practical applications such as bioprobes. Here, a series of smart near-infrared (NIR) luminogens for hyperlipidemia (HLP) diagnosis is reported. The aggregates of these molecules exhibit a twisted intramolecular charge-transfer effect in aqueous media, but aggregation-induced emission in highly viscous media due to the restriction of the intramolecular motion. These aggregates, which can autonomously respond to different environments via switching the aggregation state without changing their chemical structures are described, as "smart aggregates". Intriguingly, these luminogens demonstrate NIR-II and NIR-III luminescence with ultralarge Stokes shifts (>950 nm). Both in vitro detection and in vivo imaging of HLP can be realized in a mouse model. Linear relationships exist between the emission intensity and multiple pathological parameters in blood samples of HLP patients. Thus, the design of smart aggregate facilitates rapid and accurate detection of HLP and provides a promising attempt in aggregate science.
Collapse
Affiliation(s)
- Feiyi Sun
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Wei Zhao
- Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, P. R. China
| | - Hanchen Shen
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Ni Fan
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, P. R. China
| | - Jianyu Zhang
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Qingqing Liu
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, 999077, P. R. China
| | - Changhuo Xu
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Jiaming Luo
- Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, P. R. China
| | - Mengying Zhao
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Yuyang Chen
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Kristy W K Lam
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Xueqin Yang
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Ryan T K Kwok
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Jacky W Y Lam
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Jianwei Sun
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
| | - Hongfei Zhang
- Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, P. R. China
| | - Ben Zhong Tang
- Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Guangdong-Hong Kong-Macau Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Division of Life Science, and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, 999077, P. R. China
- School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen, 518172, P. R. China
- Center of Aggregation-Induced Emission, South China University of Technology, Guangzhou, 510640, P. R. China
| |
Collapse
|
2
|
Kaplan S, Kaplan A, Marcoe KF, Gey GO, Schiller H, Roby PV, Fisher LD, El-Massry S, Sauvage LR. The Platelet Aggregation Score and Its Correlation to β- Thromboglobulin and Platelet Factor 4 Levels. Clin Appl Thromb Hemost 2016. [DOI: 10.1177/107602969500100206] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
We describe a new method of interpreting platelet aggregometry results and its correlation to platelet secretory protein levels. We studied 123 healthy male volunteers, 37-85 years of age. The aggregation response to 2.5 μM ADP was measured in a standardized platelet suspension (SPS) prepared from platelet-rich plasma. Turbidimetic measurements included amplitude of the primary aggregation wave (Amp1), maximum aggregation amplitude (Amax), and area under the aggregation curve (Sagg). A platelet aggregation (PA) score was calculated as ( Amp1 /Amax) ·Sagg ·(whole-blood platelet count/SPS platelet count). β-Thromboglobulin (β-TG)and . platelet factor 4 (PF4) levels were measured by radioimmunoassay. The PA score correlated significantly (p < 0.0001) with β-TG ( r = 0.86) and PF4 ( r = 0.87). It was concluded that the PA score correlates closely with individual subjects' propensities to platelet activation, as reflected by plasma β-TG and PF4 levels. Key Words: Platelets-Platelet aggregometry-Platelet secretory proteins.
Collapse
Affiliation(s)
- Svetlana Kaplan
- Chemistry/Hematology, University of Washington, Seattle, Washington, U.S.A
| | - Alexander Kaplan
- Chemistry/Hematology, University of Washington, Seattle, Washington, U.S.A
| | - Karen F. Marcoe
- Chemistry/Hematology, University of Washington, Seattle, Washington, U.S.A
| | - Gerge O. Gey
- Department of Preventive Medicine, The Boeing Company, University of Washington, Seattle, Washington, U.S.A
| | - Harvey Schiller
- Clinical Laboratories, Providence Medical Center, Laboratory Medicine, University of Washington, Seattle, Washington, U.S.A
| | - Paul V. Roby
- Biostatistics, University of Washington, Seattle, Washington, U.S.A
| | - Llod D. Fisher
- Surgery Departments. The Hope Heart Institute, University of Washington, Seattle, Washington, U.S.A
| | - Sherif El-Massry
- Biostatistics, University of Washington, Seattle, Washington, U.S.A
| | - Lester R. Sauvage
- Surgery Departments. The Hope Heart Institute, University of Washington, Seattle, Washington, U.S.A., Department of Surgery, University of Washington, Seattle, Washington, U.S.A
| |
Collapse
|
3
|
Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, Van Der Bom JG. High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. J Thromb Haemost 2010; 8:906-13. [PMID: 20128867 DOI: 10.1111/j.1538-7836.2010.03786.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
SUMMARY BACKGROUND Platelets are involved in the occlusion of coronary arteries after rupture of an atherosclerotic plaque. Furthermore, activated platelets release large quantities of growth factors, chemokines and interleukins that regulate inflammatory reactions. Therefore, we hypothesized that high basal platelet reactivity may contribute to an increased risk of myocardial infarction (MI) in premenopausal women. METHODS We assessed the relation between high platelet reactivity and MI in a population-based case-control study among premenopausal women (aged < 50 years). We used multivariable logistic regression to quantify the effect of high platelet reactivity, adjusted for potential confounders. Platelet reactivity was estimated by plasma levels of neutrophil activating peptide 2 (NAP-2), CXC chemokine ligand (CXCL)4, soluble glycoprotein 1b (sGPIb) and soluble P-selectin. RESULTS High platelet reactivity (i.e. levels >or= 90th percentile control subjects) was associated with a 2- to 3-fold increased incidence of MI: the adjusted odds ratios (ORs) were 3.0 [95% confidence interval (CI) 1.4-6.4] for NAP-2, 2.2 (0.9-5.1) for CXCL4, 1.9 (0.7-4.6) for sP-selectin and 2.5 (1.1-5.7) for sGPIb. The incidence of MI dose-dependently increased when more markers were elevated. High platelet reactivity according to both NAP-2 and sGPIb was associated with an up to tenfold increased incidence (9.9, 95% confidence interval 2.0-48.3). CONCLUSIONS High basal platelet reactivity was associated with a 2- to 3-fold higher incidence of MI compared with normal platelet reactivity in premenopausal women. Our results suggest that high basal platelet reactivity may contribute to a higher risk of MI.
Collapse
Affiliation(s)
- J D Snoep
- Department Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands
| | | | | | | | | | | |
Collapse
|
4
|
Yazici M, Demircan S, Aygul E, Sahin M, Albayrak F, Aksakal E, Durupinar B, Zimmo A, Sagkan O. Effect of sedation on soluble P-selectin levels, coagulation and myocardial damage following a coronary intervention. Int J Clin Pract 2006; 60:526-32. [PMID: 16700848 DOI: 10.1111/j.1368-5031.2006.00834.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
This study was aimed to investigate the effect of sedation on plasma soluble P-selectin (sP-selectin) levels and initiation phase of coagulation following coronary intervention. A total of 58 patients with unstable angina were randomised into two groups of sedated (n = 29) and nonsedated (n = 29) patients. sP-Selectin, adrenaline, noradrenaline, von Willebrand factor (vWF), fibrinogen, platelet and troponin-I levels were measured before the intervention and at 30 min and 24 h after the intervention. In the sedated group, adrenaline, noradrenaline, sP-selectin and fibrinogen levels remained stable 30 min after the intervention (p > 0.05), whereas vWF level increased (p < 0.05). In the nonsedated group, 30-min sP-selectin (p < 0.001), adrenaline (p < 0.05), noradrenaline (p = 0.012), vWF (p < 0.001) and fibrinogen (p < 0.001) levels were found to be increased. Also, 24-h sP-selectin, vWF and fibrinogen levels for both groups showed significant increases when compared with the values both 30 h before (p < 0.001) and 30 min after the intervention (p < 0.001). Sedation before interventions reduces sP-selectin levels, initial phase of coagulation and, consequently, myocardial damage.
Collapse
Affiliation(s)
- M Yazici
- Ondokuz Mayis University Medical Faculty, Department of Cardiology and Microbiology and Clinical Microbiology, Samsun, Turkey.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Dehmer GJ, Nichols TC, Bode AP, Liles D, Sigman J, Li S, Koch G, Tate DA, Griggs TR. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. Am J Cardiol 1997; 80:871-7. [PMID: 9382000 DOI: 10.1016/s0002-9149(97)00538-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Three markers of platelet activation (platelet-derived microparticles, fibrinogen binding and expression of P-selectin) were assessed by flow cytometry during diagnostic coronary angiography and therapeutic coronary interventions. In 24 patients undergoing diagnostic angiography, blood was collected to determine if our sampling techniques or coronary angiography caused platelet activation. Changes during diagnostic angiography were used to establish baseline values and interpret changes during coronary interventions. In 21 patients, blood samples were obtained at 5 time points during percutaneous transluminal coronary angioplasty (PTCA) (n = 17) or directional coronary atherectomy (DCA) (n = 4). During coronary interventions, mean values for the percentage of platelets expressing P-selectin or binding fibrinogen increased, but with considerable variation among patients. Individual responses for platelet activation markers in each patient were characterized using a twofold increase to indicate elevation related to the intervention. Patients were classified as having complicated or uncomplicated procedures based on the presence of acute closure, dissection, or thrombus observed by angiography. There were no differences in the percentage of elevated markers between patients with uncomplicated (12.5%) and complicated (19%) PTCA procedures. However, patients treated with DCA had more elevated markers (38%) than those treated with PTCA (15%) (p = 0.04). Our data suggest that the extent of platelet activation in individual patients cannot be predicted by common angiographic findings or complications. More markers of platelet activation were present after DCA and may reflect a greater degree of vascular trauma associated with this procedure.
Collapse
Affiliation(s)
- G J Dehmer
- Center for Thrombosis and Hemostasis, Department of Medicine, University of North Carolina, Chapel Hill 27514, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Nydegger UE, Rieben R, Aeschbacher B. Biocompatibility of apheresis harness. TRANSFUSION SCIENCE 1989; 11:43-54. [PMID: 10149523 DOI: 10.1016/0955-3886(90)90006-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- U E Nydegger
- Central Laboratory of Haematology, University of Bern, Switzerland
| | | | | |
Collapse
|
7
|
Aeschbacher B, Haeberli A, Nydegger UE. Donor safety and plasma quality in automated plasmapheresis. Comparison of two filter materials. Vox Sang 1989; 57:104-11. [PMID: 2528858 DOI: 10.1111/j.1423-0410.1989.tb01145.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The level of blood cells and differential counts as well as of selected clotting and complement system components and breakdown products were measured in donor plasma of 42 polycarbonate filter (group I) and 7 nylon filter (group II) plasmapheresis procedures. Three different sampling time points were considered: (1) 1 min prior to connecting the donor to the machine (sample A); (2) 1 min after donation by a repeat venipuncture (sample B), and (3) in collected plasma (sample C). The better biocompatibility of the newly introduced nylon filters became evident on the basis of blood cell counts with significant drops of total white blood cell counts, monocytes, lymphocytes and platelets in sample B of group I, but not of group II. Similarly, complement studies revealed significant decrease of CH 50, C4 and C3 in samples B and C of group I, but only in samples C of group II. Coagulation studies showed significant increases of fibrinopeptide A and beta-thromboglobulin in samples B and C of group I; in group II beta-thromboglobulin was significantly increased in sample C compared to sample A. Plasminogen levels were decreased in samples B and C of group I but not of group II. Nonactivated partial thromboplastin time remained normal in group I. Factor VIII:C determinations in group II revealed a recovery of 86% in sample C.
Collapse
Affiliation(s)
- B Aeschbacher
- Central Laboratory of Hematology, University of Berne, Switzerland
| | | | | |
Collapse
|
8
|
Gregov D, Jenkins A, Duncan E, Siebert D, Rodgers S, Duncan B, Bochner F, Lloyd J. Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man. Br J Clin Pharmacol 1987; 24:425-34. [PMID: 2825745 PMCID: PMC1386303 DOI: 10.1111/j.1365-2125.1987.tb03194.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
1. The effect of dipyridamole on platelet function was measured in twelve normal subjects given 150 or 200 mg tablets as single and multiple doses, and in six subjects given single doses of 25, 50 and 100 mg and multiple doses of 50 mg 8 hourly. 2. Platelet aggregation was measured in response to ADP and collagen. In the subjects given 150/200 mg, the platelets were assayed for content of cyclic AMP and for formation of thromboxane after addition of collagen. The responses to ADP and collagen and the cyclic AMP content were assessed in both the presence and absence of added PGE1. The pharmacokinetics of dipyridamole were studied in all subjects. 3. One hour after 150/200 mg single doses of dipyridamole there was significant inhibition of platelet aggregation in response to both collagen and ADP. There was no detectable effect on aggregation at other time points or with lower doses of dipyridamole. The addition of PGE1 to platelets prior to testing did not enhance the effect of dipyridamole on platelet aggregation. 4. In multiple doses, dipyridamole (150/200 mg twice daily for 11 days) had no detectable effect on platelet aggregation. 5. Dipyridamole did not have any effect on platelet cyclic AMP content, whether or not PGE1 was added prior to assay. 6. Dipyridamole did not affect platelet thromboxane formation. 7. Plasma dipyridamole concentrations were maximal 1-2 h after ingestion, at the same time that inhibition of platelet aggregation was detected. The concentrations declined in a biexponential fashion, with a terminal half life of 24.1 +/- 1.9 h (mean +/- s.e. mean). In six of the 17 subjects, the mean steady state plasma concentration was less than 75% of the value predicted from the single dose data.
Collapse
Affiliation(s)
- D Gregov
- Department of Clinical and Experimental Pharmacology, University of Adelaide, South Australia
| | | | | | | | | | | | | | | |
Collapse
|
9
|
George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78:340-8. [PMID: 2942561 PMCID: PMC423547 DOI: 10.1172/jci112582] [Citation(s) in RCA: 328] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
The accurate definition of surface glycoprotein abnormalities in circulating platelets may provide better understanding of bleeding and thrombotic disorders. Platelet surface glycoproteins were measured on intact platelets in whole blood and platelet membrane microparticles were assayed in cell-free plasma using 125I-monoclonal antibodies. The glycoproteins (GP) studied were: GP Ib and GP IIb-IIIa, two of the major intrinsic plasma membrane glycoproteins; GMP-140, an alpha-granule membrane glycoprotein that becomes exposed on the platelet surface following secretion; and thrombospondin (TSP), an alpha-granule secreted glycoprotein that rebinds to the platelet surface. Thrombin-induced secretion in normal platelets caused the appearance of GMP-140 and TSP on the platelet surface, increased exposure of GP IIb-IIIa, and decreased antibody binding to GP Ib. Patients with adult respiratory distress syndrome had an increased concentration of GMP-140 and TSP on the surface of their platelets, demonstrating in vivo platelet secretion, but had no increase of platelet microparticles in their plasma. In contrast, patients after cardiac surgery with cardiopulmonary bypass demonstrated changes consistent with membrane fragmentation without secretion: a decreased platelet surface concentration of GP Ib and GP IIb with no increase of GMP-140 and TSP, and an increased plasma concentration of platelet membrane microparticles. These methods will help to define acquired abnormalities of platelet surface glycoproteins.
Collapse
|
10
|
Strauss WE, Cella G, Parisi AF, Sasahara AA. Serial studies of platelet factor 4 and beta thromboglobulin during exercise in patients with coronary artery disease. Am Heart J 1985; 110:293-9. [PMID: 2411121 DOI: 10.1016/0002-8703(85)90147-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In vivo activation of platelets can be accurately measured by radioimmunoassays of platelet factor 4 (PF4) and beta thromboglobulin (beta TG). Studies that attempt to correlate increases in PF4 and beta TG levels with exercise-induced myocardial ischemia have yielded conflicting results. To further examine the natural history of release of PF4 and beta TG we used a method of serial samplings of these proteins during and after exercise in nine normal subjects and 24 patients with coronary artery disease (CAD). Mean values for PF4 and beta TG at rest, during each stage, and immediately after treadmill exercise were the same for normal subjects and for patients with positive and negative responses to exercise-tolerance tests (ETTs). However, nonparametric analysis and regression equations disclosed differences in trends of PF4 level during exercise; PF4 levels increased in normal subjects during exercise, while patients with positive ETTs had no change in PF4 levels and patients with negative ETTs actually showed a decrease in PF4. This investigation confirmed that exercise-induced myocardial ischemia is not associated with platelet aggregation as manifested by the release of the platelet-specific proteins PF4 and beta TG. Statistical analysis suggested that prior reports of elevated levels of PF4 during exercise could have been caused by technical and methodologic difficulties that were associated with the collection and handling of the samples.
Collapse
|
11
|
Malamet R, Wise RA, Ettinger WH, Wigley FM. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. Am J Med 1985; 78:602-8. [PMID: 3157318 DOI: 10.1016/0002-9343(85)90402-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Platelet activation has been reported to occur in patients with Raynaud's phenomenon; however, the effect of calcium channel blockers and thromboxane synthetase inhibitors has not been previously studied. The effect of two drugs that potentially inhibit platelet activation were studied: nifedipine, a calcium channel blocker, and dazoxiben, a specific thromboxane synthetase inhibitor. Two platelet-specific proteins released during platelet activation, beta-thromboglobulin and platelet factor 4, were measured during a double-blind clinical trial of these two drugs in patients with Raynaud's phenomenon. The plasma beta-thromboglobulin level was significantly elevated in the patient population (53.8 +/- 7.6 ng/ml) during the placebo period compared with that in a normal control population (27.0 +/- 3.1 ng/ml) (p less than 0.01). The plasma platelet factor 4 level was 8.7 +/- 2.2 ng/ml in the patients compared with 6.5 +/- 1.0 ng/ml in the normal subjects (p = NS). These findings indicate the presence of in vivo platelet activation in patients with Raynaud's phenomenon. Nifedipine lowered the levels of beta-thromboglobulin to near the normal range (33.4 +/- 4.6 ng/ml). The inhibition of platelet activation by nifedipine was associated with clinical improvement in Raynaud's phenomenon with fewer and less intense episodes. Beta-thromboglobulin was not lowered by dazoxiben (58.1 +/- 9.0 ng/ml) compared with the placebo. The reduction of beta-thromboglobulin levels by nifedipine indicates that in vivo platelet activation was inhibited by this agent. Since this was associated with a reduced frequency of attacks, it is not clear whether this was a direct effect of the drug on platelet activation, leading to decreased frequency of vasospasm, or an effect on vascular smooth muscle leading to decreased vasospasm and a secondary decrease in platelet activation.
Collapse
|
12
|
Application of Immunologic Assays to the Coagulation Laboratory. Clin Lab Med 1984. [DOI: 10.1016/s0272-2712(18)30932-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Mant MJ, Kappagoda CT, Taylor RF, Quinlan JE. Platelet activation caused by cardiac catheter blood collection, and its prevention. Thromb Res 1984; 33:177-87. [PMID: 6230755 DOI: 10.1016/0049-3848(84)90178-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The study of platelet changes occurring across the coronary circulation is important in the investigation of the platelet's role in ischemic heart disease. It requires blood sampling through cardiac catheters. This could activate platelets and alter the results of tests of platelet activation and reactivity. This study was designed to examine this problem and to devise satisfactory methods for obtaining blood for platelet studies through long catheters. Blood collected through catheters introduced with a guide-wire had a much higher plasma heparin neutralising activity (HNA), platelet factor 4(PF4) and beta-thromboglobulin (beta TG) than peripheral venous blood, and lower platelet count(PC). Blood collected through catheters introduced via a sheath, and kept filled with anticoagulant/antiplatelet solution until blood sampling, gave results similar to peripheral venous blood for the PC, platelet aggregate ratio, platelet fluorescent granule count, and for plasma HNA, PF4 and beta TG. It is concluded that platelets are activated during blood collection through cardiac catheters; however, with appropriate precautions, blood which is satisfactory for platelet studies can be obtained.
Collapse
|
14
|
Cella G, Scattolo N, Girolami A, Sasahara AA. Are platelet factor 4 and beta-thromboglobulin markers of cardiovascular disorders? LA RICERCA IN CLINICA E IN LABORATORIO 1984; 14:9-18. [PMID: 6203164 DOI: 10.1007/bf02905035] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Beta-thromboglobulin and platelet factor 4 are the two best characterized platelet-specific proteins. They are stored in the platelet alpha-granules and released during platelet activation. Their physiological function is unknown. PF4 has high anti-heparin activity, whilst beta-TG does not. Certain factors can affect the plasma level of one or both of these two proteins and these must be borne in mind whenever the evaluation of beta-TG and PF4 are thought to represent true in vivo platelet activation: their artificial release due to sample collection and processing, the in vivo release of PF4 induced by heparin, and the elevation of beta-TG due to renal failure. What really represents an abnormal level of beta-TG and PF4 is unknown, since we do not know their pathophysiology. At present, however, the platelet-specific proteins, even if they are considered as 'markers' of platelet activation, do not necessarily reflect the severity of the cardiovascular disorders nor do they signal thrombus formation, as thrombosis is a consequence of several interacting factors.
Collapse
|
15
|
Abstract
Platelet aggregation generally is ordered by the physician to evaluate platelet function in hemorrhagic or thrombotic disorders. Malfunction of the platelet may be the result of an intrinsic congenital defect or an acquired problem induced by drugs or certain circulating plasma factors. It is necessary to obtain information from the patient with respect to family history, drug ingestion, physical or mental stress. In addition, other laboratory studies should be obtained to rule out general coagulation disorders affecting the plasma factors. A bleeding time will be helpful in establishing the severity of any platelet dysfunction. Technical considerations with regard to the preparation of the samples are of primary importance in determining platelet aggregation. Aggregating studies require the use of a variety of binding agents. (Studies on shape change, adhesion of platelets, release of platelet granule substance, and or lysis with extrusion of cytoplasmic constituents may be helpful in certain cases.) Instrumentation for platelet aggregation presently is available in many hospitals. The technical factors to be considered for routine aggregation studies include the type and strength of anticoagulant, centrifugation technique used in preparing the platelet-rich and platelet-poor plasma, platelet concentration, time of storage of the sample after venipuncture and after centrifugation, temperature, and the mixing of the sample. In general, critical concentrations of each reagent should be employed to improve the discrimination capability of the assay. Small differences in response may be obliterated by using excessive concentrations of a given reagent. Comparison in response to the test platelets with control platelets is best done at the same time by performing the aggregation in a dual instrument so that handling procedures will be identical and artifactual differences eliminated.
Collapse
|